Fidelity U.S. High Dividend Mutual Fund (FCUH)

Overview

Radiopharm Theranostics Limited is a dynamic company engaged in the cutting-edge field of radiopharmaceuticals, focusing on the research and development of innovative products for both diagnostic and therapeutic purposes. With a strong commitment to addressing areas of high unmet medical needs, Radiopharm Theranostics aims to revolutionize the approach to treating various malignancies. Incorporated in 2021 and headquartered in Carlton, Australia, the company stands at the forefront of developing solutions for some of the most challenging cancers, leveraging the power of radioisotopes to target and treat diseases at the cellular level.

Products and Services

• RAD 204

  A groundbreaking advance in cancer therapeutics, RAD 204 is designed as a targeted programmable death-ligand 1 (PD-L1) inhibitor for the treatment of non-small cell lung cancer (NSCLC). This product exemplifies Radiopharm Theranostics' commitment to developing personalized medicine options for cancer patients, offering new hope for those battling this prevalent form of lung cancer.

• RAD 202

  Focusing on the human epidermal growth factor receptor 2 (HER2), RAD 202 represents a novel approach to treating breast cancer and other solid tumors. By targeting HER2-positive cancers, this product aims to improve the efficacy and precision of cancer treatment, potentially leading to better patient outcomes and reduced side effects.

• RAD 301

  This diagnostic radiopharmaceutical is tailored for patients with pancreatic ductal adenocarcinoma, targeting avß6 integrin to enable precise imaging of pancreatic tumors. RAD 301 highlights the company’s dedication to improving diagnostic capabilities, which is crucial for the timely and accurate treatment of pancreatic cancer, one of the most lethal cancer types.

• RAD 302

  An avß6-integrin targeting agent, RAD 302 is developed for the treatment of multiple cancer types, showcasing the versatility and potential of Radiopharm Theranostics’ platform in addressing various malignancies through targeted therapy.

• RAD 101 & RAD 102

  These products are specifically designed for the treatment of brain metastases, providing targeted therapeutic options to address secondary brain tumors. This focus on metastatic brain cancers underscores the company’s commitment to tackling some of the most challenging and underserved areas in oncology.

• RAD 402

  Targeted at advanced prostate cancer, RAD 402 is a testament to the company’s pursuit of novel treatments for high-incidence cancers. By focusing on advanced stages of prostate cancer, RAD 402 aims to offer alternatives for patients who may have limited options.

• RV01

  Developed for the treatment of multiple solid tumors, RV01 exemplifies the broad potential and applicability of Radiopharm Theranostics’ research and development efforts, aiming to introduce versatile and effective options for a range of solid tumor cancers.